Search Results for “AI” – Page 593 – media

Boehringer bags first biosimilar approval in the EU

Boehringer Ingelheim has won its first biosimilar approval in Europe with authorisation of Cyltezo for a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
- Source: Pharmatimes
- 594
- November 16, 2017
arthritis biosimilar chronic Cyltezo New Approvals
Loxo Oncology Lands $1.55B Cancer Tie-Up With Bayer

Loxo Oncology struck a deal with Germany-based Bayer AG to develop and commercialize two cancer therapies in a deal that could be worth up to $1.55 billion for the Connecticut-based company.
- Source: Biospace
- 832
- November 16, 2017
cancer larotrectinib Market Views therapy TRK
Cholesterol Crystals Are Sure Sign A Heart Attack May Loom

A new Michigan State University study on 240 emergency room patients shows just how much of a role a person's cholesterol plays, when in a crystallized state, during a heart attack.
- Source: scienmag
- 535
- November 15, 2017
atherosclerosis cholesterol coronary arteries Researches
Eight cases of tuberculosis confirmed at Hong Kong secondary school

The Hong Kong health authorities have confirmed that eight people from a secondary school in Sha Tin were infected with tuberculosis.
- Source: scmp
- 532
- November 15, 2017
Market Views tuberculosis
AstraZeneca-FASENRA Gets US FDA Approval For Severe Eosinophilic Asthma

AstraZeneca and its global biologics research and development arm, MedImmune, said Tuesay that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype. FASENRA is not approved for the treatment of other eosinophilic conditions or relief of acute bronchospasm or status asthmaticus.
- Source: businessinsider
- 568
- November 15, 2017
asthma eosinophilic Market Views New Approvals
Perflow Medical Announces Issuance of Patent for The Stream™ Dynamic Neuro-Thrombectomy Net to Improve Thrombus Removal Post-Stroke

Perflow Medical, an Israeli-based medtech company focused on next-generation neurointerventional devices,announced the issuance of U.S. Patent No. 9510855, by the U.S. Patent and Trademark Office (USPTO), for the Stream™ Dynamic Neuro-Thrombectomy Net. This is the first device to provide full dynamic wall apposition during the treatment of acute ischemic stroke.
- Source: Prnewswire
- 540
- November 15, 2017
ischemic stroke neurointerventional New Approvals
US regulators approve first digital pill to track patients

US regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns. The digital pill approved Monday combines two existing products: the former blockbuster psychiatric medication Abilify—long used to treat schizophrenia and bipolar disorder—with a sensor tracking system first approved in 2012.
- Source: medicalxpress
- 506
- November 15, 2017
bipolar disorder blockbuster New Approvals psychiatric schizophrenia
Gene prompts cells to store fat, fueling obesity

Obesity is often attributed to a simple equation: People are eating too much and exercising too little. But evidence is growing that at least some of the weight gain that plagues modern humans is predetermined.
- Source: sciencedaily
- 642
- November 14, 2017
ankyrin-B gene obesity Researches
Study reveals how a very low calorie diet can reverse type 2 diabetes

In a new study, a Yale-led research team uncovers how a very low calorie diet can rapidly reverse type 2 diabetes in animal models. If confirmed in people, the insight provides potential new drug targets for treating this common chronic disease, said the researchers.
- Source: Medicalxpress
- 540
- November 14, 2017
calorie chronic diabetes Researches
Amgen makes regenerative medicine play, backing $25M Fortuna round to move neural stem cells into the clinic

Amgen’s VC wing has invested in Fortuna Fix to help move autologous neural stem cells into the clinic. The $25 million series B sets regenerative medicine startup Fortuna up to move candidates against Parkinson’s disease and spinal cord injury to clinical trials next year.
- Source: Fiercebiotech
- 561
- November 14, 2017
Amgen autologous neural stem cells Series

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.